BNP Paribas Financial Markets
AUPH icon

BNP Paribas Financial Markets’s Aurinia Pharmaceuticals AUPH Stock Holding History

BNP Paribas Financial Markets’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42M Sell
437,037
-311,728
-42% -$4.98M ﹤0.01% 1816
2026
Q1 		$11.1M Buy
748,765
+123,081
+20% +$1.8M 0.01% 1511
2025
Q4 		$9.98M Buy
625,684
+204,326
+48% +$2.9M ﹤0.01% 1621
2025
Q3 		$4.66M Buy
421,358
+408,324
+3,133% +$4.46M ﹤0.01% 2030
2025
Q2 		$110K Buy
13,034
+3,191
+32% +$25.6K ﹤0.01% 3985
2025
Q1 		$79.1K Sell
9,843
-8,232
-46% -$66.7K ﹤0.01% 4126
2024
Q4 		$162K Sell
18,075
-14,003
-44% -$114K ﹤0.01% 3975
2024
Q3 		$235K Buy
32,078
+20,324
+173% +$126K ﹤0.01% 3196
2024
Q2 		$67.1K Sell
11,754
-66,712
-85% -$351K ﹤0.01% 3385
2024
Q1 		$393K Buy
78,466
+8,398
+12% +$57K ﹤0.01% 2975
2023
Q4 		$630K Sell
70,068
-19,492
-22% -$161K ﹤0.01% 2663
2023
Q3 		$696K Buy
89,560
+54,477
+155% +$533K ﹤0.01% 2536
2023
Q2 		$340K Sell
35,083
-20,759
-37% -$215K ﹤0.01% 2782
2023
Q1 		$612K Buy
55,842
+22,976
+70% +$202K ﹤0.01% 2611
2022
Q4 		$142K Sell
32,866
-31,535
-49% -$183K ﹤0.01% 3123
2022
Q3 		$484K Buy
64,401
+34,078
+112% +$295K ﹤0.01% 3009
2022
Q2 		$305K Sell
30,323
-26,008
-46% -$291K ﹤0.01% 2908
2022
Q1 		$697K Buy
56,331
+56,228
+54,590% +$869K ﹤0.01% 2557
2021
Q4 		$2.36K Sell
103
-1,690
-94% -$40K ﹤0.01% 3984
2021
Q3 		$39.7K Buy
+1,793
New +$28.5K ﹤0.01% 3567

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's AUPH Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Aurinia Pharmaceuticals (AUPH) stake by 42% in Q2 2026, selling an estimated $4.98M and leaving 437,037 shares worth $7.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

BNP Paribas Financial Markets first reported a position in AUPH in Q3 2021 and has held it in 20 quarters since. The position peaked at $11.1M in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • BNP Paribas Financial Markets held 437,037 shares of Aurinia Pharmaceuticals worth $7.42M as of Q2 2026.
  • BNP Paribas Financial Markets sold 311,728 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $4.98M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1816 holding.
  • BNP Paribas Financial Markets first reported a position in Aurinia Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • BNP Paribas Financial Markets's Aurinia Pharmaceuticals position peaked at $11.1M in Q1 2026.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.